Alesta Therapeutics is engaged in developing innovative therapies aimed at treating cancer by targeting chronic stress response pathways. The company focuses on small molecule biotech programs that address synthetic lethal metabolic dependencies essential for cancer cell survival. By targeting specific control mechanisms involved in these pathways, Alesta Therapeutics aims to provide new therapeutic approaches that can effectively disrupt the growth of cancer cells, thereby enhancing treatment options for patients.
Alveron Pharma is focused on developing innovative treatments for hemorrhagic stroke and various thromboembolic disorders, addressing significant unmet medical needs. The company’s lead product, OKL-1111, is an injection solution designed to reduce hematoma expansion in cases of intracranial hemorrhage, moving away from complex pre-treatment processes. Additionally, Alveron is working on a cyclodextrin-based anticoagulant reversal drug, which aims to provide effective solutions for excessive bleeding related to conditions such as hemophilia, trauma, and surgical procedures. By advancing its coagulation technology, Alveron Pharma strives to enhance therapeutic options for medical practitioners dealing with acute and long-term bleeding complications.
Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.
Tacalyx GmbH is an oncology company based in Berlin, Germany, specializing in the discovery and development of Tumor-Associated Carbohydrate Antigens (TACAs) as innovative targets for cancer therapy. Originating as a spin-off from the Max-Planck-Institute of Colloids and Interfaces, Tacalyx leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures are essential for generating and identifying antibodies aimed at developing new therapeutics. TACAs are characterized by their specific expression in tumors, which arises from abnormal glycosylation and is associated with promoting metastasis, angiogenesis, and immune system suppression. By combining sophisticated synthesis capabilities with comprehensive analysis and screening, Tacalyx aims to create novel immunotherapies that effectively stimulate anti-cancer responses.
Artica Therapeutics focuses on biotechnological research and development aimed at creating innovative therapies for severe autoimmune and inflammatory disorders. The company employs label-free cellular-based screening methods to facilitate the rapid advancement of drug candidates. This approach enhances the efficiency of the drug discovery process, ultimately enabling healthcare professionals to provide effective treatments for patients suffering from these challenging conditions. Additionally, Artica Therapeutics is involved in the development of medical devices and pharmaceutical processes, expanding its impact within the healthcare sector.
Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models.
Gradient Denervation Technologies is a Paris-based company founded in 2019 that focuses on the development of an endovascular catheter-based medical device designed to treat pulmonary hypertension. This innovative technology aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics through a minimally invasive procedure. The device is built on prior research and intellectual property developed at Stanford University and offers a novel approach to pulmonary artery denervation, addressing heart failure and associated pulmonary hypertension. By providing a reliable and effective treatment option, the company seeks to improve patient outcomes in the healthcare industry.
FundaMental Pharma is a neuroscience company focused on developing innovative treatments for neurological diseases at the preclinical stage. The company creates neuroprotective molecular spacers aimed at preventing neurodegeneration in the brain. Utilizing peptides and gene therapy, FundaMental Pharma specializes in diagnosing polymorphisms and is dedicated to developing a novel class of drugs that target untreatable neurological conditions. Through its research, the company seeks to provide pharmacological solutions for patients suffering from various challenging neurological disorders.
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
InnoSIGN specializes in mRNA-based pathway activity profiling technology, aimed at advancing precision medicine by offering deeper insights into disease mechanisms. The company leverages a comprehensive library of pathway activity profiles to enhance diagnostics and facilitate drug discovery. It provides researchers with quantitative PCR (qPCR) tests designed for decentralized use, which are available through a service testing facility located in the Netherlands. Through its innovative approach, InnoSIGN seeks to transform the understanding and treatment of various diseases.
Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models.
ATRO Medical B.V., based in Nijmegen, the Netherlands, focuses on developing innovative solutions for knee joint health through its anatomically shaped meniscus implant, the Trammpolin. This implant is designed to restore the protective function of the meniscus by acting as a joint spacer, thus alleviating pain and improving life quality for patients suffering from osteoarthritis. The company emerged as a spin-out from DSM and Radboudumc, leveraging insights gained from a collaborative initiative that began in 2010, involving various universities and private enterprises with support from the Dutch government. The Trammpolin prosthesis is a synthetic, non-resorbable substitute that mimics the natural meniscus, functioning effectively as a shock absorber by ensuring adequate load distribution within the knee joint.
Alveron Pharma is focused on developing innovative treatments for hemorrhagic stroke and various thromboembolic disorders, addressing significant unmet medical needs. The company’s lead product, OKL-1111, is an injection solution designed to reduce hematoma expansion in cases of intracranial hemorrhage, moving away from complex pre-treatment processes. Additionally, Alveron is working on a cyclodextrin-based anticoagulant reversal drug, which aims to provide effective solutions for excessive bleeding related to conditions such as hemophilia, trauma, and surgical procedures. By advancing its coagulation technology, Alveron Pharma strives to enhance therapeutic options for medical practitioners dealing with acute and long-term bleeding complications.
EsoBiotec is a Belgian biotechnology company dedicated to the discovery and development of novel cancer therapies. The firm focuses on empowering the human body to combat cancer through in vivo cell engineering. By creating innovative immunotherapies, EsoBiotec aims to provide cost-effective drugs and therapeutics that enhance accessibility, ensuring that patients can receive essential cancer treatments at lower costs.
Kinetyx Sciences Inc., founded in 2020 and based in Calgary, Canada, specializes in the development of sensor-based in-shoe solutions designed for various sports and performance applications. The company focuses on creating sensory insoles that capture high-fidelity data at the interface between the foot and ground. This technology enables the collection of laboratory-quality data in real-world environments, facilitating innovative training, study, competition, and play. By providing valuable insights, Kinetyx aims to enhance athletic performance, extend athletic longevity, and support recovery from injuries, thereby empowering individuals to maintain an active lifestyle.
Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.
NutriLeads is a startup focused on developing innovative natural food ingredients that offer clinically proven health benefits. The company specializes in precision prebiotic fibers derived from crops, which are designed to enhance immunity and support various physiological processes in the human body. By collaborating with food industry partners, NutriLeads aims to identify promising lead ingredients and create sustainable production methods. The company also initiates scientific and clinical programs to validate the health effects of its ingredients, facilitating their integration into dietary supplements and specialized functional food and beverage products for consumers. Through these efforts, NutriLeads strives to advance nutritional health innovation across the food sector.
Indigo Diabetes nv (Indigo) is a young high-tech medical device company founded by Danaë Delbeke and her team ended in 2016. Indigo develops the world’s first invisible sensor for people living with diabetes to address their need for accurate glucose monitoring with improved user experience. Indigo exploits groundbreaking photonics technology that revolutionized the Internet during the last decades and now aims at transforming diabetes management.
Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models.
Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.
Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.
Mellon Medical provides suturing tools for surgeons to improve medical procedures. The company's goal is to help medical specialists improve patient outcomes by providing them with the best possible suturing tools. It commercializes surgical instruments to allow single-handed stitching, enabling efficient and effective suturing of tubular and layered structures. Mellon Medical was established in 2013 and is headquartered in Nijmegen, Gelderland.
ATRO Medical B.V., based in Nijmegen, the Netherlands, focuses on developing innovative solutions for knee joint health through its anatomically shaped meniscus implant, the Trammpolin. This implant is designed to restore the protective function of the meniscus by acting as a joint spacer, thus alleviating pain and improving life quality for patients suffering from osteoarthritis. The company emerged as a spin-out from DSM and Radboudumc, leveraging insights gained from a collaborative initiative that began in 2010, involving various universities and private enterprises with support from the Dutch government. The Trammpolin prosthesis is a synthetic, non-resorbable substitute that mimics the natural meniscus, functioning effectively as a shock absorber by ensuring adequate load distribution within the knee joint.
NutriLeads is a startup focused on developing innovative natural food ingredients that offer clinically proven health benefits. The company specializes in precision prebiotic fibers derived from crops, which are designed to enhance immunity and support various physiological processes in the human body. By collaborating with food industry partners, NutriLeads aims to identify promising lead ingredients and create sustainable production methods. The company also initiates scientific and clinical programs to validate the health effects of its ingredients, facilitating their integration into dietary supplements and specialized functional food and beverage products for consumers. Through these efforts, NutriLeads strives to advance nutritional health innovation across the food sector.
Indigo Diabetes nv (Indigo) is a young high-tech medical device company founded by Danaë Delbeke and her team ended in 2016. Indigo develops the world’s first invisible sensor for people living with diabetes to address their need for accurate glucose monitoring with improved user experience. Indigo exploits groundbreaking photonics technology that revolutionized the Internet during the last decades and now aims at transforming diabetes management.
MILabs specializes in high-end molecular imaging solutions designed for biomedical, pharmaceutical, and university research. The company manufactures multimodal and integrated imaging systems, including micro-PET, micro-SPECT, micro-CT scanners, and optical tomography systems. These advanced technologies are utilized in the diagnosis of various diseases, such as diabetes, cancer, and neurodegenerative disorders. MILabs aims to provide clients with diagnostic tools that are characterized by user-friendly operation, facilitating efficient workflows in research and clinical settings. Their systems play a significant role in the global development of new diagnostic methods.
NightBalance B.V. is a company established by alumni of TU Delft, originating from research conducted at the Delft University of Technology in 2007 focused on enhancing positional therapy aids. Founded in 2009, NightBalance specializes in the development of the Sleep Position Trainer, a smart therapeutic device designed to address sleep apnea. This innovative therapy monitors patients' sleep behavior and actively prevents positional obstructive sleep apnea, allowing individuals to achieve more comfortable and restful sleep.
NutriLeads is a startup focused on developing innovative natural food ingredients that offer clinically proven health benefits. The company specializes in precision prebiotic fibers derived from crops, which are designed to enhance immunity and support various physiological processes in the human body. By collaborating with food industry partners, NutriLeads aims to identify promising lead ingredients and create sustainable production methods. The company also initiates scientific and clinical programs to validate the health effects of its ingredients, facilitating their integration into dietary supplements and specialized functional food and beverage products for consumers. Through these efforts, NutriLeads strives to advance nutritional health innovation across the food sector.
FABPulous is a healthcare company based in The Netherlands, founded as a spin-off from Maastricht University in 2008. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created a novel handheld disposable plasma separation device that enables rapid preparation of plasma from a drop of blood, facilitating point-of-care and home testing. This device can be integrated with various in vitro diagnostic platforms, such as lateral flow devices. The primary product under development is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which aids in the first-line diagnosis of acute myocardial infarction. By providing a simple and efficient diagnostic tool, FABPulous aims to enhance the speed and accuracy of medical assessments in critical care settings.
Hemics is a medical device company focused on enhancing the quality of life for patients with Rheumatoid Arthritis (RA) through innovative imaging technology. The company develops non-invasive devices that utilize a patented Optical Inflammation Detection technology, which allows for the fast and objective quantification of inflammation. This technology aids rheumatologists in monitoring and assessing disease activity in the joints, particularly in the hands, facilitating more effective treatment strategies. Founded as a spin-out from Royal Philips Electronics, Hemics aims to provide an operator-independent solution that supports rheumatologists in their clinical assessments of inflammatory conditions associated with RA.
Cristal Therapeutics BV is a clinical-stage pharmaceutical company based in Maastricht, the Netherlands, founded in 2011. The company specializes in developing nanomedicines using its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted therapy. This advanced technology aims to enhance the efficacy of both new and existing drugs by improving their delivery to specific tissues and cells, thereby addressing significant medical needs, particularly in cancer treatment. Cristal Therapeutics focuses on creating versatile nanomedicine solutions that can facilitate better outcomes in various therapeutic areas through innovative polymeric constructs.
EnCare Biotech B.V. is a biopharmaceutical company based in Utrecht, the Netherlands, established in 2014. The company specializes in the development of therapeutic monoclonal antibodies, particularly focusing on its Fibronectin-EDA monoclonal antibody aimed at preventing chronic heart failure following acute myocardial infarction. EnCare's approach integrates a solid scientific foundation with expertise in manufacturing, regulatory affairs, and clinical development, supported by a network of specialists in these fields. The management team has extensive experience in business development and has successfully executed partnerships across the industry. EnCare operates with a lean business model, maintaining in-house control over key functions while outsourcing operational activities to top-tier external providers. This structure allows EnCare to focus on delivering innovative therapies that enhance patient outcomes in heart failure prevention.
NightBalance B.V. is a company established by alumni of TU Delft, originating from research conducted at the Delft University of Technology in 2007 focused on enhancing positional therapy aids. Founded in 2009, NightBalance specializes in the development of the Sleep Position Trainer, a smart therapeutic device designed to address sleep apnea. This innovative therapy monitors patients' sleep behavior and actively prevents positional obstructive sleep apnea, allowing individuals to achieve more comfortable and restful sleep.
Mellon Medical provides suturing tools for surgeons to improve medical procedures. The company's goal is to help medical specialists improve patient outcomes by providing them with the best possible suturing tools. It commercializes surgical instruments to allow single-handed stitching, enabling efficient and effective suturing of tubular and layered structures. Mellon Medical was established in 2013 and is headquartered in Nijmegen, Gelderland.
Hemics is a medical device company focused on enhancing the quality of life for patients with Rheumatoid Arthritis (RA) through innovative imaging technology. The company develops non-invasive devices that utilize a patented Optical Inflammation Detection technology, which allows for the fast and objective quantification of inflammation. This technology aids rheumatologists in monitoring and assessing disease activity in the joints, particularly in the hands, facilitating more effective treatment strategies. Founded as a spin-out from Royal Philips Electronics, Hemics aims to provide an operator-independent solution that supports rheumatologists in their clinical assessments of inflammatory conditions associated with RA.
TheraSolve NV is a medical technology company dedicated to developing and commercializing innovative, user-friendly, and cost-effective solutions to promoting medication adherence. TheraSolve’s patented technology platform will motivate broad patient populations to take their medications as prescribed, and more generally, to perform any health-promoting activity in a timely fashion.
NightBalance B.V. is a company established by alumni of TU Delft, originating from research conducted at the Delft University of Technology in 2007 focused on enhancing positional therapy aids. Founded in 2009, NightBalance specializes in the development of the Sleep Position Trainer, a smart therapeutic device designed to address sleep apnea. This innovative therapy monitors patients' sleep behavior and actively prevents positional obstructive sleep apnea, allowing individuals to achieve more comfortable and restful sleep.
Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company employs advanced antibody engineering technology to develop treatments for rare autoimmune conditions. Its notable product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address unmet medical needs in the field of immunology.
FABPulous is a healthcare company based in The Netherlands, founded as a spin-off from Maastricht University in 2008. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created a novel handheld disposable plasma separation device that enables rapid preparation of plasma from a drop of blood, facilitating point-of-care and home testing. This device can be integrated with various in vitro diagnostic platforms, such as lateral flow devices. The primary product under development is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which aids in the first-line diagnosis of acute myocardial infarction. By providing a simple and efficient diagnostic tool, FABPulous aims to enhance the speed and accuracy of medical assessments in critical care settings.
CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.
DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based vaccines share all immune‐stimulatory properties with patient-derived dendritic cell‐based vaccines, and have the simple logistics of off‐the‐shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.
Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.
Bioceros B.V. is a biopharmaceutical research and development contract organization based in Utrecht, the Netherlands. Established in 2003, the company specializes in providing a comprehensive range of services for the early pre-clinical development of recombinant proteins, particularly monoclonal antibodies. Its expertise encompasses assay development, molecular biology, cell biology, immunology, protein expression, upscaling, fermentation, protein purification, and consulting. Bioceros serves a diverse clientele, including biotech firms, academic institutions, and pharmaceutical companies, facilitating their progress from initial discovery to pre-clinical development. By offering an integrated approach from DNA to drug product, Bioceros aims to support the advancement of medicinal products and contribute to patient care.
CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.
Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.
Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.
Galapagos NV is a clinical-stage biotechnology company based in Mechelen, Belgium, that focuses on discovering, developing, and commercializing small molecule medicines. The company’s clinical programs include filgotinib, a JAK1 inhibitor undergoing trials for multiple conditions such as rheumatoid arthritis and Crohn’s disease, as well as GLPG1690, an autotaxin inhibitor in trials for idiopathic pulmonary fibrosis and systemic sclerosis. Additionally, Galapagos is developing GLPG1205, a GPR84 inhibitor for idiopathic pulmonary fibrosis, and GLPG1972 for osteoarthritis. The company also explores Toledo molecules for inflammation. Galapagos has established collaborations with several pharmaceutical companies, including Gilead Sciences and AbbVie. Founded in 1999, Galapagos aims to address diseases with high unmet medical needs and improve patient outcomes globally.
EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in developing innovative pharmaceutical products aimed at treating pain and cancer. The company employs a unique topical delivery approach for its prescription pain medications, which allows for targeted drug administration, distinguishing its products from traditional systemic or transdermal methods. EpiCept is focused on establishing partnerships for co-marketing, co-promotion, licensing, and distribution of its products, thereby enhancing its market presence. The company has implemented a robust patent strategy to protect its product portfolio, which is anticipated to possess significant market potential.
Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.
Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.
Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.
Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.
Breonics focuses on biomedical research and development, specifically in the area of organ and tissue transplants. The company has developed Exsanguinous Metabolic Support (EMS) technology, which significantly expands the criteria for organ donation. This innovative technology addresses the limitations that currently restrict access to potential kidney donors, allowing healthcare practitioners to maintain the oxidative metabolism and function of organs while they are isolated from the human body. As a result, EMS has the potential to double the number of transplantable kidneys available worldwide, ultimately improving outcomes for patients in need of transplants.
Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets biological products for the biosurgical and immunotherapy markets.
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.
Vernalis Limited is a commercial stage pharmaceutical company based in Cambridge, United Kingdom, focused on the research, development, and commercialization of products for various medical disorders. The company offers several products, including Tuzistra XR for the U.S. cough-cold market, Moxatag, a once-daily amoxicillin formulation for treating tonsillitis and pharyngitis, and frovatriptan for migraine relief. Vernalis also engages in licensing agreements to develop and commercialize additional products in the cough-cold sector. The company integrates advanced research techniques, including structural biology and medicinal chemistry, to facilitate drug discovery across both established and novel therapeutic targets. Vernalis operates as a subsidiary of Ligand Pharmaceuticals and has been active since its incorporation in 1988.
Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands. Avantium's proprietary high-throughput technology enables a faster and more cost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development. Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields: new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent. Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business. Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations.